Asset Details
Do you wish to reserve the book?
Alpha 5 integrin as a prognostic biomarker for survival in carcinomas: a systematic review
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Alpha 5 integrin as a prognostic biomarker for survival in carcinomas: a systematic review
Do you wish to request the book?
Alpha 5 integrin as a prognostic biomarker for survival in carcinomas: a systematic review
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Alpha 5 integrin as a prognostic biomarker for survival in carcinomas: a systematic review
2025
Overview
Altered integrin expression in carcinomas has been associated with tumor aggressiveness, including survival outcomes. The alpha 5 (α5) integrin is associated with increased proliferation, invasion, migration, and metastasis in various types of cancer, however there is no systematic review on its potential as a prognostic marker for survival outcomes. This systematic review analyzed studies reporting α5 integrin detection by immunohistochemistry and associated survival outcomes, retrieved from PubMed, Embase, Scopus, and the Cochrane Library databases. Fourteen publications met the inclusion criteria including a total of 2,018 patients diagnosed with ovarian, colorectal, liver, cervical, esophageal, pancreatic ductal, tongue or bladder carcinoma. The survival outcomes assessed in these studies included overall survival (OS), progression-free survival (PFS), recurrence-free survival (RFS), and percent survival. Eleven studies reported a positive association between elevated α5 integrin expression and poorer OS or percent survival, while two found no association. Reduced PFS was associated with elevated α5 integrin expression in three studies, whereas two studies reported no such association. One study evaluated α5 integrin expression in relation to RFS and found no association. In conclusion, there is evidence that increased α5 integrin expression is associated with poorer overall and progression-free survival in carcinomas. However, these findings should be further validated through additional research to confirm its potential as a prognostic marker.
